Critical Therapeutics to Present at the 2008 BIO CEO & Investor Conference on Tuesday, February 12

LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) announced today that it will present at the 2008 BIO CEO & Investor Conference on Tuesday, February 12, 2008, at 3:30 p.m. (ET) at The Waldorf=Astoria in New York.

Management will provide an update on the Company’s operations, development pipeline and milestones. A live and archived webcast of this presentation will be available by logging on to the “Investors” section of the Company’s website, www.crtx.com, and clicking the link labeled “Webcasts & Presentations.”

About Critical Therapeutics

Critical Therapeutics, Inc. is developing and commercializing innovative products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to two FDA-approved drugs for the prevention and chronic treatment of asthma in patients 12 years of age and older: twice-daily ZYFLO CR™ (zileuton) extended-release tablets and ZYFLO® (zileuton tablets). Critical Therapeutics is developing products for acute asthma attacks that lead patients to the emergency room and other urgent care settings. The Company also is developing therapies directed toward the body’s inflammatory response. Critical Therapeutics is located in Lexington, Mass. For more information, please visit www.crtx.com.